State of Maine Antibiogram

2018 Data



Maine Center for Disease Control

Healthcare Epidemiology

 Released:

 September 2019

**Background:**

Antimicrobial resistance is an ever-increasing public health problem with an estimated 2 million people infected each year in the United States with antibiotic resistant bacteria, and around 23,000 of those die as a result.5 Tracking such resistance to antibiotics is crucial in antimicrobial stewardship efforts nationally. A state antibiogram offers such tracking and trending through a cumulative aggregation of all local antibiograms in the state.

In the aggregation of data, antibiograms for calendar year 2018 were requested from all 32 acute and critical access hospitals in Maine, and are included in the state antibiogram. The report contains a gram-negative antibiogram and a gram-positive antibiogram with an overview of the organism antibiotic combinations most all hospitals provided. A distinction was not made between inpatient and outpatient isolates in all laboratories; additionally, not all laboratories distinguished between urine and systemic isolates. Providers should refer to their local antibiogram as the first line of guidance for clinical therapy.

**State Antibiogram Uses:**

Comparative analysis to prior years cannot be performed at this time as this is Maine’s first state antibiogram. A state antibiogram can be used for:

* Comparisons in susceptibility rates at the local vs. state level, as well as the state to other states in the northeast region to guide antimicrobial stewardship efforts, inform antibiotic resistance reduction strategies, and to develop education campaigns
* Out-of-country providers treating infected patients with acquired infection originating in Maine
* Target interventions and prevention strategies around antimicrobial resistance
* Tracking and trending statewide changes in percent susceptibility over time

Citation:

 [Centers for Disease Control and Prevention](http://www.cdc.gov/), [National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)](https://www.cdc.gov/ncezid/dw-index.html), [Division of Healthcare Quality Promotion (DHQP)](https://www.cdc.gov/ncezid/dhqp/index.html)



KEY: Blank Cell: Insufficient data or no isolates tested R: Intrinsic Resistance or poor efficacy

**Physicians should access their local antibiogram for empirical therapy**

****



KEY: Blank Cell: Insufficient data or no isolates tested R: Intrinsic Resistance or poor efficacy

Physicians should access their local antibiogram for empirical therapy

